Dr. Ding Lingwen's research interests focus on developing innovative therapeutic strategies to overcomeresistance to cancer immunotherapy and identifving genetic and epigenetic abnormalities in cancers and precancerous conditions. He has authored 73 manuscripts in international journals, over half of them werepublished in journals with impact factor >10. He also served as an invited ad hoc reviewer and reviewed ovel465 manuscripts for 142 international journals. Over the past few years, he has successfully secured morethan 2.2 milion SGD in research funding as the Principal Investigator (Pl), and 6.3 milion SGD as CoInvestigator and Collaborator. He also contributes as a Team Principal investigator to a CRP (CompetitiveResearch Programme, 7.8 milion SGD) grant from NRF. He was the recipient of the prestigious Lee Kuan YewPostdoctoral Fellowship and the Year 2021 Gilead Research Scholars Award (Hematology and Oncology)